Home Blog Page 1498

Lorikeet Voice 2.0 Powers Real-Time Support for Hundreds of Thousands During SNAP Emergency Rollout

By
Advertorial Desk
-

In partnership with GiveCard, Lorikeet’s conversational intelligence platform for high-complexity support assisted more than 300,000 families and resolved issues at a moment of urgent need.

SAN FRANCISCO, Dec. 12, 2025 /PRNewswire/ — Lorikeet, the company transforming customer support experiences with universal AI concierges, today announces the launch of Lorikeet Voice 2.0 (“Voice 2.0”), conversational AI agents that coordinate with other agents and third parties to resolve complex situations without human handoffs. Voice 2.0 has proven its effectiveness at scale in real-world, high-stress conditions, serving as the frontline support for emergency financial assistance and food aid across the United States.

“Voice AI has to do more than sound human,” said Steve Hind, Co-Founder and CEO of Lorikeet. “It has to deliver real resolution. Voice 2.0 can answer a question while simultaneously rebooking a flight, messaging a hotel, and spawning a specialist agent to verify a payment or fix an account issue. No other system can do that. This is how companies move from scripted automation to intelligent support that anticipates needs, manages complexity, and creates true customer delight.”

Proven impact during a critical moment of need
Voice 2.0 recently served as the frontline support system for GiveCard during a high-pressure emergency aid rollout for SNAP recipients across multiple states. Thousands of families needed immediate help accessing emergency funds via physical and virtual cards, and Voice 2.0 ensured they could do so quickly and confidently at a moment when support demand surged to unprecedented levels.

Lorikeet’s GiveCard agents were deployed and went live in just a single weekend. Since launch, Voice 2.0 has:

  • Supported more than 300,000 people seeking financial assistance
  • Answered more than 60,000 calls (and counting) from GiveCard cardholders

Unlike basic chatbots or traditional voice systems, Voice 2.0 resolved issues end-to-end rather than simply answering questions. Callers received 24/7 help with:

  • Program eligibility and fund access
  • Card activation and claim code verification
  • Troubleshooting redemption issues
  • Guidance through GiveCard’s standard operating procedures
  • Accurate, context-specific instructions tailored to each caller’s situation

By acting as an intelligent and scalable extension of GiveCard’s support team, Voice 2.0 eliminated long wait times, cleared bottlenecks, and made it possible for families in crisis to access essential funds without delay.

“During a difficult and stressful situation, we could rely on Lorikeet voice agents to guide cardholders through the process of accessing their benefits with clarity and care,” said Sofia Pedro, Head of Product at GiveCard. “Lorikeet’s support was critical to successfully managing caller needs, ensuring families received critical resources and peace of mind.”

How Voice 2.0 works
Voice 2.0 is a new class of conversational intelligence designed not just to talk to customers, but also to autonomously resolve their needs end-to-end. It uses multi-agent intelligence, real-time reasoning, and deep system integration to handle complex situations that traditional voice AI cannot. Key features include:

  • Active Intelligence and Context Awareness: Voice 2.0 reviews the customer’s history, context, and prior interactions as the call unfolds, proactively surfacing relevant information without additional back-and-forth.
  • Parallel Multi-Agent Coordination: While one agent speaks naturally with the customer, other agents handle verification, fraud checks, itinerary changes, account updates, or vendor coordination.
  • Instant Channel Switching Across Phone, Text, and Email: Support continues seamlessly even if the customer switches devices or channels. The system maintains context across every interaction.
  • Adaptive Tone and Context Tracking: Voice 2.0 detects tone, urgency, emotion, and context switching, adjusting its communication style to meet customers where they are while monitoring every detail to build trust.
  • Clarity Before Action: Before taking meaningful action, Voice 2.0 confirms intent and details. This ensures accuracy and protects customers and businesses alike.
  • Smart Escalation: The system knows when a situation requires human intervention and escalates with full context, so customers never need to repeat themselves.
  • Human-Like Flow and Low Latency: The experience feels natural and responsive, with low-latency replies and human-like pacing that builds rapport while retaining computational precision.
  • Multilingual Support: Voice 2.0 supports English, Spanish, Mandarin, and 20+ additional languages, expanding access and inclusivity for diverse customers.

Lorikeet’s growth plans for 2026
Lorikeet continues to expand its multi-agent platform for customer experience globally. The company has offices serving North America, EMEA, and APAC, with customers in banking, healthcare, insurance, and other industries that require high-quality customer experiences while meeting strict compliance standards.

Lorikeet’s approach focuses on enabling actions rather than only providing answers. In particular, its multi-agent approach addresses infrastructure gaps in regulated industries by coordinating with third parties and working seamlessly within systems, even where API integrations are limited, allowing organizations to automate multi-party workflows.

ABOUT LORIKEET
Lorikeet builds AI-powered customer concierges that solve real problems, not just answer questions. With its industry-first Team of Agents platform, Lorikeet enables multiple specialized agents to collaborate in real-time across chat, email, voice, and SMS to deliver end-to-end resolutions. Founded in Australia and backed by QED Investors, Blackbird, Square Peg, and Airtree, Lorikeet is redefining what’s possible in customer support. Learn more at lorikeetcx.ai.

Media Contact:
Tess Pawlisch
608-333-9788
lorikeet@needlepr.com

ZOWIE Elevates Esports Performance at Budapest Major 2025

By
Advertorial Desk
-

 LEVEL UP AS ONE: Empowering Pro Players and Teamwork in Pursuit of Perfection on the World Stage

BUDAPEST, Hungary, Dec. 12, 2025 /PRNewswire/ — ZOWIE by BenQ Corporation, leading esports brand preferred by professional players, is proud to provide its proven XL2586X+ monitor at StarLadder Budapest Major 2025. As a trusted partner of the world’s top teams, ZOWIE brings its tournament philosophy — LEVEL UP AS ONE — to life this year, standing strong behind players and fueling team performance. Watch this spirit in action in the video https://bit.ly/3MkUtou. Global audience can also join the ZOWIE Fan Power Challenge to vote for their favorite teams and engage with the tournament in real time. Join now: https://bit.ly/3KDIqlI.

ZOWIE Sports Science Lab (Netherland)
ZOWIE Sports Science Lab (Netherland)

The global esports market is estimated at over USD 2.13 billion in 2024 and projected to reach around USD 7.46 billion by 2030, with a compound annual growth rate (CAGR) of 23.1%.1 Building on this momentum, ZOWIE continues to deepen its investment in esports technology to empower players. “For more than a decade, ZOWIE has worked hand-in-hand with industry partners and professional players to develop equipment that meets the highest standards of competition. Looking ahead, we’ll continue to support tournament organizers and players as they elevate the competitive experience, empower players, and drive innovation — truly leveling up as one together,” said Jay Wu, President of BenQ Europe B.V.

Redefining Esports Display Standards: ZOWIE XL2586X+

Trusted by 88% of CS2 professional players worldwide,2 ZOWIE continues to strength its presence in esports, with the XL2586X+ serving as the official monitor of StarLadder Budapest Major 2025. The XL2586X+ — featuring a 600 Hz Fast-TN panel and the latest DyAc 2 implementation — delivers unparalleled motion clarity and responsiveness, helping players reduce motion blur during rapid movements to locate opponents and aim more quickly. Its industrial-grade, bearing-based stand allows easier and smoother height adjustment, helping players quickly find their preferred setup. Designed for peak performance, XL2586X+ reflects ZOWIE’s commitment to helping players dominate the game. For more product details, please visit: https://bit.ly/48SwiXo.

From Lab to Pro Play: Science Drives Performance

Rooted in the FPS community, ZOWIE embraces a player-centered philosophy, designing every product around the demands of competitive play. At ZOWIE’s Sports Science Labs worldwide, researchers employ motion capture and electromyography (EMG) to help players better understand their own hand motions, muscle responses, and endurance levels. These findings validate designs that improve individual performance and guide players toward the mouse shape that best suits their playstyle. With seven distinct shapes in the DW wireless series, including EC-DW’s rounded and smooth-curve design that avoids distracting pressure on the palm,3 ZOWIE aims to provide stable control throughout extended play. 

Built with the Pros: Turn Insights into Competitive Advantage

Built to help players win, ZOWIE transforms pro player insights into competitive advantages. Each mouse shape delivers faster, more controlled execution. In addition, the enhanced receiver reduces interference by improving signal stability and minimizing frame drops or stuttering during gameplay. For monitors, best-in-class motion clarity and tournament-standard performance allow players to identify opponents faster and compete confidently on any stage. These improvements come from the way ZOWIE continually gathers insights from professional players through long-term collaboration and hands-on testing, integrating real in-game feedback into product refinement.

1Grand View Research (2024): Esports Market (2025 – 2030)

2 ProSettings.net (2025): Best Monitor for CS2 [887 Pro Players, Nov 2025]

3 ZOWIE: EC3-DW | ZOWIE Europe

About ZOWIE / BenQ Corporation 

Established in 2008, ZOWIE is a top esports brand for professional players, focusing on player-centric design and dedicated to providing esports gear for professional FPS players. In 2015, ZOWIE joined BenQ Corporation, combining its expertise with BenQ’s robust R&D resources and leading panel innovative capabilities. ZOWIE remains committed to driving excellence in product design through scientific research. With 70% of professional players using ZOWIE products, the brand continues to successfully deliver serious gear technology to global players. For more information, please visit:  https://zowie.benq.eu/en-eu/campaign/best-gaming-monitor-for-cs-major.html 

ZOWIE Sports Science Lab (Taiwan - Headquarters)
ZOWIE Sports Science Lab (Taiwan – Headquarters)

From Left to Right: Celsa Wu, Head of Esports Business at BenQ Europe B.V.; Jay Wu, President of BenQ Europe B.V.
From Left to Right: Celsa Wu, Head of Esports Business at BenQ Europe B.V.; Jay Wu, President of BenQ Europe B.V.

StarLadder Budapest Major 2025 Official Monitor XL2586X+
StarLadder Budapest Major 2025 Official Monitor XL2586X+

TraceLink Supports UNICEF’s Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally

By
Advertorial Desk
-

TraceLink announced its support for UNICEF’s Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By supporting TRVST, TraceLink reinforces its position as the leading platform for global traceability and patient protection. 

BOSTON, Dec. 12, 2025 /PRNewswire/ — TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced its support for UNICEF’s Traceability and Verification System (TRVST)—a global initiative designed to strengthen health systems by improving the safety, authenticity, and traceability of medicines distributed in regions where supply chains face elevated risks of falsified or substandard products.

By supporting TRVST, TraceLink reinforces its position as the market’s leading platform for global traceability and patient protection, contributing to worldwide efforts to secure medicine quality, strengthen public health infrastructure, and ensure that every patient can trust the medicine they receive.

UNICEF’s TRVST Strengthens Global Medicine Traceability
The Traceability and Verification System (TRVST) is a digital platform developed by UNICEF to help governments and supply partners verify and trace medicines, vaccines, and other health products throughout the supply chain.

According to the World Health Organization, an estimated 1 in 10 medical products circulating in certain regions may be falsified or of substandard quality. TRVST directly addresses this global challenge by giving health authorities and partners a secure, standardized digital tool to ensure product legitimacy, maintain treatment continuity, and protect patient safety.

Built on GS1 global data standards, TRVST serves as a centralized repository of product and event information, enabling:

  • Verification of serialized medicines to confirm authenticity.
  • Tracking of product movement to identify potential diversion or falsification.
  • Visibility from manufacturing through delivery at the point of care.

For countries expanding their digital and regulatory capacity, TRVST provides a reliable, scalable foundation for medicine verification and safe, transparent access to life-saving therapies.

TraceLink Empowers TRVST with Proven Global Serialization and Traceability Expertise
As the proven digital backbone for more than 40 global track-and-trace and serialization mandates, TraceLink delivers secure product identification and data exchange across the pharmaceutical supply chain.

By aligning with TRVST, TraceLink helps advance a globally connected network of trusted medicine data, ensuring that the same technology supporting commercial compliance also strengthens humanitarian health systems.

TraceLink’s Leadership Reaffirms Commitment to Patient Safety

“TraceLink was founded on a simple but vital mission: to ensure that every patient can trust the medicine they receive,” said Shabbir Dahod, President and CEO of TraceLink. “Wherever organizations operate—and whatever the local traceability requirements may be—TraceLink stands ready as a trusted platform to help ensure safe, authentic medicines reach the patients who depend on them.”

TraceLink’s Support of UNICEF TRVST Advances Global Health Resilience
TraceLink’s support of UNICEF’s TRVST reflects a long-standing commitment to public health and regulatory readiness. With over 15 years of experience enabling serialization and traceability across global markets, TraceLink continues to help organizations:

  • Meet evolving compliance and interoperability standards.
  • Prevent counterfeit and diverted medicines from reaching patients.
  • Build more transparent and resilient pharmaceutical supply chains.
  • Establish the digital network and real-time information foundations required for transformative leaps in AI-enabled, end-to-end digital supply chains.

Together, UNICEF’s leadership and TraceLink’s technology strengthen the foundation of global health supply networks, ensuring that every patient, everywhere, receives medicines that are genuine, safe, and effective.

Frequently Asked Questions

Q: What is UNICEF’s Traceability and Verification System (TRVST)?
A: Developed by UNICEF, TRVST helps governments and partners verify and trace medicines, vaccines, and other health products across the supply chain, ensuring reliable product access and authenticity.

Q: How does TraceLink support TRVST?
A: By aligning with TRVST, TraceLink helps advance a globally connected network of trusted medicine data, ensuring that the same technology supporting commercial compliance also strengthens humanitarian health systems.

Q: Why is this partnership important?
A: Substandard and falsified medicines remain a major global health threat. TRVST and TraceLink support the integrity of the medicine supply chain, ensuring that patients worldwide receive safe and authentic products.

Q: How does this align with TraceLink’s mission?
A: TraceLink was founded to protect patients by ensuring every pharmaceutical product is safe. Supporting TRVST extends that mission into humanitarian health systems and global public health.

About TRVST

UNICEF’s Traceability and Verification System (TRVST) is part of the Verification and Traceability Initiative (VTI), supporting national health authorities and global procurement partners in building traceability infrastructure for medicines and vaccines. It is designed to improve visibility, accountability, and patient safety by leveraging GS1 standards and interoperable data exchange.

About TraceLink

TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by linking more than 291,000 healthcare and life sciences entities through its Business-to-Network Integrate-Once™ network. Leading companies trust TraceLink to deliver complete global digitalization, visibility, and traceability of healthcare products, ensuring that every patient receives the medicines they rely on, safely, securely, and on time. 

ACE Shutters Notorious Piracy Operations in India

By
Advertorial Desk
-

MKVCinemas and Illicit Cloning Tool Accounted for More Than 373 Million Global Visits Between 2024 and 2025

LOS ANGELES, Dec. 12, 2025 /PRNewswire/ — The Alliance for Creativity and Entertainment (ACE), the world’s leading antipiracy coalition, has dismantled India-based piracy network MKVCinemas and its associated domains. Additionally, ACE shut down a high-traffic drive-to-drive cloning tool frequently used by piracy services in India and Indonesia.

Most of MKVCinemas’ traffic came from India, a rapidly expanding entertainment market.

Collectively, the MKVCinemas domains accounted for 142.4 million global visits between 2024 and 2025. The piracy tool received 231.4 million visits in the same time period.  

Following an extensive investigation, ACE identified the operator in Bihar, India, who agreed to shut down the operation and transfer 25 associated domains. 

The shuttered drive-to-drive cloning tool was relied on by major piracy services in the region. Cloning tools copy files directly from a concealed cloud repository into a user’s own cloud drive, allowing pirates to keep the source concealed to evade effective takedown processes.

“Piracy isn’t a harmless shortcut as it exposes consumers to real risks and drains resources from India’s creative economy,” said Larissa Knapp, Executive Vice President, and Chief Content Protection Officer at the Motion Picture Association. “Our actions make clear that ACE will relentlessly pursue and dismantle illegal operations so audiences and creators can benefit from a secure, sustainable marketplace.”

The MKVCinemas domains are being redirected to ACE’s “Watch Legally” page.

About The Alliance for Creativity and Entertainment

The Alliance for Creativity and Entertainment (ACE) is the world’s leading coalition dedicated to protecting the legal creative market and reducing digital piracy. Driven by a comprehensive approach to addressing piracy through criminal referrals, civil litigation, and cease-and-desist operations, ACE has achieved many successful global enforcement actions against illegal streaming services and unauthorized content sources and their operators. Drawing upon the collective expertise and resources of more than 50 media and entertainment companies around the world—including sports channels and associations—and reinforced by the Motion Picture Association’s content protection operations, ACE protects the creativity and innovation that drives the global growth of core copyright and entertainment industries. The current governing board members for ACE are Amazon, Apple TV, Netflix, Paramount Pictures, Sony Pictures, Universal Studios, The Walt Disney Studios, and Warner Bros. Discovery. Charles Rivkin is Chairman and CEO of the Motion Picture Association and Chairman of ACE.

Suvoda IRT named a Leader in Everest Group’s RTSM PEAK Matrix®

By
Advertorial Desk
-

CONSHOHOCKEN, Pa., Dec. 11, 2025 /PRNewswire/ — Suvoda, a global clinical trial technology company, today announced that its IRT (Interactive Response Technology) software, also known as RTSM (Randomization and Trial Supply Management), has been recognized as a Leader in Everest Group’s PEAK Matrix® assessment for RTSM technology.

Everest Group’s PEAK Matrix® is a rigorous, data-driven evaluation of technology providers, benchmarking market impact alongside vision and delivery capability. The assessment includes direct customer interviews, providing insight into real-world performance and user experience. This acknowledgment underscores Suvoda’s strong market adoption, innovation, and technical strength in the RTSM space.

“Suvoda demonstrates specialization in managing high-complexity and multi-arm studies, enabled by its low-code/no-code platform, Virtual Partition framework, and strong integration network,” said Nisarg Shah, Practice Director at Everest Group. “Its modular architecture, flexible study configuration, and ongoing investments in AI-enabled automation earn it a Leader position in the Everest Group’s Life Sciences RTSM Products PEAK Matrix® Assessment 2025.”

“We are honored to be named a Leader by Everest Group. This recognition reaffirms that Suvoda IRT delivers unparalleled capabilities and speed for randomization and supply management in complex clinical trials,” said Jagath Wanninayake, CEO of Suvoda. “It also reflects how we continue to advance our platform, bringing IRT together with our broader suite of products to manage the most critical, time-sensitive moments of each study for our customers.”

Suvoda IRT serves as a “command and control center” for clinical trial logistics, enabling sponsors, CROs, and sites to deliver the right treatment to the right patient at the right time. Built on configurable architecture, Suvoda IRT supports even the most complex protocols and features real-time inventory visibility and predictive resupply. The system can quickly adapt to mid-study changes via customization tools built into the Suvoda Platform, which is supported by several issued patents that recognize the company’s innovation. Suvoda IRT sets the new standard in the industry, transforming the clinical trial experience for sponsors, CROs, sites, and patients by making the overall journey more intuitive.

To further enhance usability, Suvoda recently introduced Sofia, an AI assistant that simplifies drug supply manager tasks by streamlining data retrieval, monitoring inventory and reviewing visit schedules, and creating data visualizations, all within a conversational interface. The system also delivers real-time analytics through pre-set and ad-hoc reports so that teams can make informed decisions quickly.

For more information, access the Everest Group report on Suvoda IRT here.

About Suvoda
Suvoda is a global clinical trial technology company with a real-time experience platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Suvoda merged with Greenphire, a leading provider of clinical trial financial management and patient support tools. To learn more, visit suvoda.com and follow Suvoda on LinkedIn.

CONTACT: 
Robin Abadía
Director, External Communications
marketing@suvoda.com

Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports. 

Logo – https://laotiantimes.com/wp-content/uploads/2025/12/suvoda_updated_logo.jpg

Gravity Launches Hybrid Casual Game ‘Ragnarok Monster Kitchen’ Worldwide!

By
Advertorial Desk
-
  • A restaurant management game where Ragnarok monsters take on the role of chefs, featuring an intuitive UI and fast-paced gameplay
  • Delivers fresh fun through event modes like special guests, delivery time-attacks, and boss challenges
  • Available for download and immediate play on Google Play and the Apple App Store in supported regions

SEOUL, South Korea, Dec. 12, 2025 /PRNewswire/ — Global game company Gravity officially launched the hybrid casual game ‘Ragnarok Monster Kitchen’ on December 11 in global regions, excluding select countries.

Ragnarok Monster Kitchen became available at 17:00 KST on December 11 in global regions excluding Korea, Japan, and China. Players can download the game from Google Play or the Apple App Store in supported regions and begin playing immediately.

Ragnarok Monster Kitchen is a hybrid casual restaurant-management game where iconic monsters from the Ragnarok universe take on the role of chefs and run their own kitchens. The game features a simple, intuitive interface and a fast-paced gameplay loop that makes it easy to pick up, offering a clear sense of progress even in short sessions. Players advance through themed restaurant stages, unlocking new dishes and recipes along the way. Beloved monsters like Poring, Savage Bebe and Wild Rose appear as chefs, adding a playful visual charm to the experience.

The game offers a variety of event-driven activities—including managing restaurant tasks, handling special guests, racing against the clock in delivery challenges, and battling bosses—that add fresh layers of fun to the experience. Players can further personalize and strengthen their chef monsters through costume and pet collection systems, while the stage-based progression structure delivers a steady sense of growth and immersion. By reimagining the charm of the Ragnarok IP in an accessible way, the game provides accessible, enjoyable gameplay for players around the world.

Pre-registration for Ragnarok Monster Kitchen has been available on Google Play and the Apple App Store since December 2. The game was first launched in Indonesia last September, where it delivered strong retention and long playtime metrics—performance that helped build confidence in its global rollout.

Jeong In-hwa, PM of Ragnarok Monster Kitchen at Gravity, said, “This title offers a unique twist by letting Ragnarok monsters take on the role of chefs while players manage their own restaurants. We designed the game so that the charm of the casual genre can be fully enjoyed with simple, intuitive controls.” He added, “We are preparing a variety of content updates and events tailored for global service, and we look forward to players’ continued interest and support.”

More information about the official launch of Ragnarok Monster Kitchen is available on the game’s official website (https://rmk.gnjoy.com/).


[Gravity Official Website] http://www.gravity.co.kr 

[Ragnarok Monster Kitchen Official Website] https://rmk.gnjoy.com/

[Ragnarok Monster Kitchen Google Play Download Page] https://play.google.com/store/apps/details?id=com.gravity.romk.aos 

[Ragnarok Monster Kitchen Apple App Store Download Page]

https://apps.apple.com/id/app/ragnarok-monster-kitchen/id6749607765

[Ragnarok Monster Kitchen Official Discord] https://discord.com/invite/T6wNuERtW4

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

By
Advertorial Desk
-

– Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease  leveraging Everest’s existing commercial organization
– Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the Company’s late-stage product pipeline
– Together, these agreements drive financial and strategic synergies,  improve utilization and productivity of our existing commercial platform, and strengthen commercial capabilities and life-cycle management, while establishing an attractive vertical in cardiovascular disease

SHANGHAI, Dec. 11, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest’s existing sales and marketing organization to provide commercialization services for a portfolio of Hasten’s mature assets.

The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is expected to be indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China. The Commercial Services Agreement is expected to close in 1H 2026, subject to customary closing conditions, while the Licensing Agreement will close immediately. Both agreements do not impact Everest’s 2025 financial guidance.

Everest is expected to benefit from these two transactions by realizing synergies from XERAVA and Hasten’s critical care portfolio including Rocephin and Stilamin across complementary geographic footprints, channel access and hospital coverage, and enhancing commercialization capabilities and life-cycle management of innovative medicines. Everest also expects to generate a recurring income stream from the service fees, thereby improving utilization and productivity of its existing commercial platform. By leveraging established infrastructure, sales team and key account relationships, the Company believes that it will be able to deliver incremental  sales while enhancing the scale, experience and effectiveness of its own commercial organization. Together, these two agreements strengthen Everest’s commercial foundation in China and expand its presence in the large and growing cardiovascular market. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest’s cardiovascular portfolio.

Commercialization Service Agreement Deal Terms:

The Commercialization Service Agreement with Hasten covers six approved and commercially available products across three major therapeutic areas:

  • Critical care: Rocephin®(ceftriaxone), Stilamin®（somatostatin), and Ebrantil® （urapidil)
  • Cardiovascular disease: Edarbi® (azilsartan), Blopress® (candesartan)
  • Metabolic disorders: Basen® (voglibose),

Everest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20% to 55%.  The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028 are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.

Lerodalcibep Licensing Agreement Deal Terms:

The agreement grants Everest the exclusive license to develop, register and commercialize Lerodalcibep in Greater China, together with a royalty-free, exclusive license to use Hasten’s trademarks for the product in the territory. Pursuant to the license agreement, Everest Medicines China will make an initial payment of US$29 million (approximately RMB 205 million), and may pay up to US$30 million (RMB 212 million) in potential development and regulatory milestone payments and up to US$280 million (RMB1977 million) in potential sales milestones, in addition to royalties based on the total, aggregate annual net sales.

Lerodalcibep, developed by privately-held and U.S.-based company LIB Therapeutics, is expected to be indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more patient friendly and convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. In large, global phase 3 clinical trials in over 2,500 patients, Lerodalcibep has demonstrated sustained LDL-C reductions of >60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and >55% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations. In addition, the head-to-head LIBerate-VI study, comparing Lerodalcibep with Inclisiran, demonstrated the superiority of Lerodalcibep (p=0.0319). Lerodalcibep is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. These LDL-C reductions have been confirmed in a recent phase 3 clinical trial in a Chinese population with, or at very high risk of, CVD including FH.

Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).‌ In Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.

Multiple PCSK9 inhibitors are currently approved and marketed in China, with a combined market size of approximately RMB 3 billion and year-over-year revenue growth of 95% in 2024. The market is expected to further increase to approximately RMB10 billion in 2030, according to a Frost & Sullivan report. Despite an estimated 400 million individuals in China with dyslipidemia, only ~14% receive lipid-lowering treatment, reflecting low penetration and significant unmet medical need. Lerodalcibep has patent exclusivity in China through 2039.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases，autoimmune disorders and ophthalmic diseases For more information, please visit its website at www.everestmedicines.com.

About Hasten

Hasten Biopharmaceutical Co., Ltd., (Hasten), which integrates R&D, production and commercial promotion and covers the whole industrial chain, was established in 2020. Hasten is committed to building a premier commercial platform and becoming a leader in the healthcare industry. Adhering to the patient-centric philosophy, Hasten will fully leverage sustainable, self-sustaining commercialization capabilities to accelerate the value realization of high-quality products, provide innovative therapeutic solutions to benefit patients and create social value.

For more information, please view website: www.hastenpharma.com.

 Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

 

Milesight Releases White Paper on Europe’s Smart Building Transition, Highlighting €32.8 Billion Market Shift Driven by Policy and Technology

By
Advertorial Desk
-

XIAMEN, China, Dec. 11, 2025 /PRNewswire/ — Milesight, a leading provider of innovative IoT products, recently released its white paper, “Policy-Driven Development of Smart Buildings in Europe.”

The white paper delivers a timely analysis of the forces reshaping Europe’s built environment, as stringent EU policies like the Energy Performance of Buildings Directive (EPBD) intersect with an aging building infrastructure. With 85% of structures built before 2000 and a renovation rate of just 1%, Europe’s building stock faces pressing modernization needs—creating a projected €32.8 billion retrofit opportunity.

In response to this opportunity, Milesight introduces its FES Plus framework, integrating Facility (F), Energy (E), and Space (S) Management with People Sensing intelligence (Plus). Powered by LoRaWAN’s retrofit-friendly features—easy deployment, deep coverage, and ultra-low power—the framework turns compliance into strategic value. Its core components deliver targeted outcomes: Facility Management enables BACS-compliant monitoring, Energy Management drives 2030 decarbonization goals, and Space Management ensures healthy IAQ standards. Centered on People Sensing, the system transforms static buildings into adaptive environments that balance regulatory requirements with human-centric experience.

“‘People’ is the ‘plus’ that elevates our smart building vision beyond mere efficiency,” said Andy Lee, Sales Director at Milesight. “Occupancy, activity, and comfort are what shape building performance. By sensing occupancy and behavior, we create compliant, efficient spaces that are fundamentally human-centric.”

The white paper underscores that the transition to smart buildings is no longer optional—it’s a strategic imperative shaped by policy, market demand, and technological advancement. Milesight’s FES Plus framework offers a scalable, interoperable path to not only meet these evolving standards but to exceed them—turning compliance into lasting competitive advantage.

Access the full white paper

Explore the FES Plus Framework

About Milesight

Milesight offers multi-potential sensing products to capture the most meaningful data and makes it accessible across diverse applications. It innovatively applies emerging technologies such as Al, 5G, and loT to distinct use scenarios. With a commitment to making sensing matter, Milesight quickly responds to customer-specific challenges and collaborates with an expanding network of partners to deliver unique data value. It is determined to make real, positive impacts in smart buildings, intelligent traffic, intelligent security, smart cities, and beyond.

Media Contact:

iot.marketing@milesight.com

1...1,4971,4981,499...6,441Page 1,498 of 6,441